20:07 EST Cathie Wood’s ARK Investment bought 167K shares of Crispr Therapeutics today
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRSP:
- Crispr Therapeutics announces FDA approval for Casgevy
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
- Crispr Therapeutics call volume above normal and directionally bullish
- Baird finds ‘incremental negative’ in Crispr’s 2024 outlook
- Crispr Therapeutics announces 2024 outlook
